Yumanity Therapeutics Inc
1.63 - 1.68
0.95 - 13.9
Join Discuss about YMTX with like-minded investors
Next Dividend Date
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.
CEO: Meenu Chhabra
HQ: 80 Guest St Fl 5 Boston, 02135-2071 Massachusetts